Jerel Davis, PhD, Chairman

Managing Director, Versant Ventures
Jerel Davis, PhD, Chairman

Jerel is a Managing Director based at Versant Ventures. Since joining Versant in 2011, he has played a critical role in launching and investing in a number of Versant’s portfolio companies including Quanticel Pharmaceuticals, Crispr Therapeutics, Blueline Bioscience, Northern Biologics and several of the Inception Sciences discovery start-ups.

He has also led Versant’s execution of build-to-buy structured acquisitions with Celgene, Roche and Bayer. Over the last few years, Jerel has focused on establishing Versant’s presence in Canada, including the launch of new companies in Vancouver, Toronto and Montreal. Prior to joining Versant, Jerel was Associate Principal at McKinsey and Company where he advised healthcare corporations in pharmaceuticals, biotechnology, medical device and molecular diagnostics. He has worked in a number of healthcare markets globally including the US, Europe, China, Russia and India. Jerel was a post doctoral researcher at Stanford University until 2005 and in research at Amgen from 1999-2000.

Brendan Bulik-Sullivan, PhD

Partner, GV
Brendan Bulik-Sullivan, PhD

Dr. Brendan Bulik-Sullivan is a partner at GV focusing on life sciences investments. Before GV, Dr. Bulik-Sullivan worked on applied statistics and machine learning research in genetics and biotechnology. Dr. Bulik-Sullivan led machine learning at Gritstone Oncology, where he designed machine learning models for personalized immuno-oncology therapeutics. Prior to that, he worked at the Broad Institute where he developed statistical methods for human genetics research. His research has been published in top journals including Nature, Science, Nature Biotechnology and Nature Genetics.

Dr. Bulik-Sullivan holds a B.A. in mathematics from the University of California, Berkeley and a PhD in statistical genetics from Vrije Universiteit Amsterdam.

Hao Wu, PhD

Harvard Medical School and the Boston Children’s Hospital
Hao Wu, PhD

Dr. Wu is Asa and Patricia Springer Professor of Structural Biology in the Department of Biological Chemistry and Molecular Pharmacology at the Harvard Medical School and Senior Investigator in the Program in Cellular and Molecular Medicine at the Boston Children’s Hospital. She is internationally recognized for elucidating several fundamental themes in signal transduction of the immune system using structural biology approaches.

Prior to her appointment at Harvard, Dr. Wu was Professor at Weill Cornell Medical College. She completed postdoctoral training at Columbia University in the laboratory of Professor Wayne Hendrickson and her PhD in Biochemistry from Purdue University in 1992, working in the laboratory of Professor Michael Rossmann. Dr. Wu received her pre-medical training at Peking University and studied Medicine at Peking Union Medical College.

Dr. Wu has received a number of honors, including the Howard Hughes Medical Institute pre-doctoral fellowship, the Aaron Diamond postdoctoral fellowship, the Pew Scholar award, the Rita Allen Scholar award, New York Mayor’s Award for Excellence in Science and Technology, the Margaret Dayhoff Memorial Award from the Biophysical Society and most recently, the Dorothy Crowfoot Hodgkin Award from the Protein Society and the 2019 Seymour & Vivian Milstein Award for Excellence in Interferon and Cytokine Research. She serves on the Scientific Advisory Council of the Cancer Research Institute and the Editorial Board of Cancer Cell.

Marcelo Bigal, MD, PhD

President and Chief Executive Officer
Marcelo Bigal, MD, PhD

Dr. Bigal is the President and CEO of Ventus Therapeutics. He is also a Venture Partner at Versant Ventures. He brings over 15 years of pharmaceutical experience spanning R&D, medical and scientific affairs. Marcelo held multiple leadership roles in industry including Head of R&D, CSO and CMO at TEVA. Before joining Teva, Marcelo was CMO at Labrys, where he led the team that developed fremanezumab and other medicines in neurology, psychiatry, pain and respiratory diseases approved in the US, Canada and EU. Prior to Labrys, Marcelo worked at Merck.

Prior to his work in the pharmaceutical industry, Marcelo was a faculty member at the Albert Einstein College of Medicine, Department of Neurology, as well as the Director of Research at New England Center for Headache and Director of Research at Montefiore Headache Center. He has authored around 335 papers in peer-reviewed journals, and is the recipient of multiple recognitions including the prestigious American Academy of Neurology Harold-Wolff John Graham Award for outstanding achievements in neurology research.

He holds a Medical Doctorate degree from the College of Medicine at the University of São Paulo, Brazil, where he also obtained a Masters in Science and a PhD in Neurosciences. He completed his post-doctoral research at the New England Center for Headache in CT.